BACKGROUND: The purpose of this study was to investigate the possibility of early survival prediction after completion of one cycle of neoadjuvant chemotherapy (NAC) by positron emission tomography (PET)/computed tomography (CT) with (18)F-fluorodeoxyglucose (FDG). METHODS: Fifty-seven patients with advanced head and neck squamous cell carcinoma (HNSCC) underwent FDG-PET/CT scans twice, before and after one cycle of NAC. We calculated the maximal standardized uptake value (SUV(max)) for a primary tumor and/or metastatic lymph nodes and defined %decrease as the %difference in SUV(max) between the two scans divided by that of the initial scan. Patients were classified as responders by PET (%decrease ≥55.5% or post-NAC SUV(max) ≤3.5) and by RECIST (≥30% decrease in size). The local control (LC) rate and the disease-specific survival (DSS) rate were assessed between the responders and non-responders. Multivariate analysis was also performed using the Cox proportional hazards model. RESULTS: In univariate analysis, the PET finding of a primary site was a significant risk factor for LC and DSS rates at 2 years after completion of NAC (P = 0.03 and 0.02, respectively), but there was no difference between responders and non-responders by the RECIST criteria. In a multivariate regression analysis, the PET finding in the primary site and the definitive therapy choice were independent prognostic factors in LC, while the PET finding in the primary site was the only independent prognostic factor in DSS. CONCLUSION: Our preliminary data indicate that the PET finding in the primary lesion after one cycle of NAC was an independent prognostic factor in LC and DSS in patients with HNSCC.
BACKGROUND: The purpose of this study was to investigate the possibility of early survival prediction after completion of one cycle of neoadjuvant chemotherapy (NAC) by positron emission tomography (PET)/computed tomography (CT) with (18)F-fluorodeoxyglucose (FDG). METHODS: Fifty-seven patients with advanced head and neck squamous cell carcinoma (HNSCC) underwent FDG-PET/CT scans twice, before and after one cycle of NAC. We calculated the maximal standardized uptake value (SUV(max)) for a primary tumor and/or metastatic lymph nodes and defined %decrease as the %difference in SUV(max) between the two scans divided by that of the initial scan. Patients were classified as responders by PET (%decrease ≥55.5% or post-NAC SUV(max) ≤3.5) and by RECIST (≥30% decrease in size). The local control (LC) rate and the disease-specific survival (DSS) rate were assessed between the responders and non-responders. Multivariate analysis was also performed using the Cox proportional hazards model. RESULTS: In univariate analysis, the PET finding of a primary site was a significant risk factor for LC and DSS rates at 2 years after completion of NAC (P = 0.03 and 0.02, respectively), but there was no difference between responders and non-responders by the RECIST criteria. In a multivariate regression analysis, the PET finding in the primary site and the definitive therapy choice were independent prognostic factors in LC, while the PET finding in the primary site was the only independent prognostic factor in DSS. CONCLUSION: Our preliminary data indicate that the PET finding in the primary lesion after one cycle of NAC was an independent prognostic factor in LC and DSS in patients with HNSCC.
Authors: David L Schwartz; Joseph Rajendran; Bevan Yueh; Marc D Coltrera; Michael Leblanc; Janet Eary; Kenneth Krohn Journal: Arch Otolaryngol Head Neck Surg Date: 2004-12
Authors: Mitchell Machtay; Mona Natwa; Jocelyn Andrel; Terry Hyslop; P Rani Anne; Jororsali Lavarino; Charles M Intenzo; William Keane Journal: Head Neck Date: 2009-02 Impact factor: 3.147
Authors: Corneline J Hoekstra; Sigrid G Stroobants; Egbert F Smit; Johan Vansteenkiste; Harm van Tinteren; Pieter E Postmus; Richard P Golding; Bonne Biesma; Frans J H M Schramel; Nico van Zandwijk; Adriaan A Lammertsma; Otto S Hoekstra Journal: J Clin Oncol Date: 2005-11-20 Impact factor: 44.544
Authors: Eva Brun; Elisabeth Kjellén; Jan Tennvall; Tomas Ohlsson; Anders Sandell; Roland Perfekt; Roland Perfekt; Johan Wennerberg; Sven Erik Strand Journal: Head Neck Date: 2002-02 Impact factor: 3.147
Authors: J F Ensley; J R Jacobs; A Weaver; J Kinzie; J Crissman; J A Kish; G Cummings; M Al-Sarraf Journal: Cancer Date: 1984-09-01 Impact factor: 6.860
Authors: Oleg Schmidt-Kittler; Thomas Ragg; Angela Daskalakis; Martin Granzow; Andre Ahr; Thomas J F Blankenstein; Manfred Kaufmann; Joachim Diebold; Hans Arnholdt; Peter Muller; Joachim Bischoff; Detlev Harich; Gunter Schlimok; Gert Riethmuller; Roland Eils; Christoph A Klein Journal: Proc Natl Acad Sci U S A Date: 2003-06-13 Impact factor: 11.205
Authors: M Hecht; S Semrau; M Beck; J Hartwich; M Eckstein; D Schmidt; A O Gostian; S Müller; S Rutzner; U S Gaipl; J von der Grün; T Illmer; M G Hautmann; G Klautke; J Döscher; T Brunner; B Tamaskovics; A Hartmann; H Iro; T Kuwert; R Fietkau Journal: Ann Nucl Med Date: 2022-05-10 Impact factor: 2.258
Authors: Israel Zighelboim; Jason D Wright; Feng Gao; Ashley S Case; L Stewart Massad; David G Mutch; Matthew A Powell; Premal H Thaker; Eric L Eisenhauer; David E Cohn; Fidel A Valea; Angeles Alvarez Secord; Lynne T Lippmann; Farrokh Dehdashti; Janet S Rader Journal: Gynecol Oncol Date: 2013-04-13 Impact factor: 5.482
Authors: Remco de Bree; Gregory T Wolf; Bart de Keizer; Iain J Nixon; Dana M Hartl; Arlene A Forastiere; Missak Haigentz; Alessandra Rinaldo; Juan P Rodrigo; Nabil F Saba; Carlos Suárez; Jan B Vermorken; Alfio Ferlito Journal: Head Neck Date: 2017-08-17 Impact factor: 3.147
Authors: Renata Fockink Dos Anjos; Dalton Alexandre Dos Anjos; Danielle Leal Vieira; André Ferreira Leite; Paulo Tadeu de Souza Figueiredo; Nilce Santos de Melo Journal: Medicine (Baltimore) Date: 2016-08 Impact factor: 1.889